Unaudited Results for Quarter and Nine Months Ended December 31, 2024
Vadodara, January 30, 2025 –
Paushak Limited (BSE: 532742), a leading specialty chemicals manufacturer, announced its unaudited financial results for the third quarter (Q3 FY2025) and nine-month period ended December 31, 2024. The results were reviewed by the statutory auditors and approved by the Board of Directors during their meeting on January 30, 2025.
Key Financial Highlights (₹ in Lakhs)
| Particulars | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | 9M FY2025 | 9M FY2024 | FY2024 (Audited) |
|---|
| Revenue from Operations | 4,926 | 5,731 | 5,181 | 15,859 | 15,244 | 20,626 |
| Other Income | 631 | 366 | 306 | 1,413 | 1,336 | 2,049 |
| Total Income | 5,557 | 6,098 | 5,487 | 17,272 | 16,580 | 22,675 |
| Profit Before Tax (PBT) | 1,720 | 1,689 | 1,836 | 4,848 | 4,506 | 7,099 |
| Profit After Tax (PAT) | 1,526 | 1,420 | 1,363 | 3,977 | 3,610 | 6,375 |
| Earnings Per Share (EPS) (₹) | 49.51 | 46.09 | 44.21 | 129.04 | 117.12 | 176.35 |
Performance Analysis
- Revenue Trends: The company's revenue from operations stood at ₹4,926 lakh for Q3 FY2025, down 14% QoQ and 5% YoY. However, the nine-month revenue grew 4% YoY to ₹15,859 lakh.
- Profitability: PBT for Q3 FY2025 was ₹1,720 lakh, reflecting a 2% QoQ increase, while PAT rose to ₹1,526 lakh, a 7% QoQ increase.
- Earnings Growth: EPS for Q3 FY2025 stood at ₹49.51, up from ₹46.09 in Q2 FY2025 and ₹44.21 in Q3 FY2024, indicating YoY and QoQ growth.
- Operational Efficiency: The company maintained its profitability with controlled expenses and stable margins.
Segment-Wise Performance
- The company operates in a single reportable segment, i.e., specialty chemicals, focusing on phosgene derivatives.
Auditor’s Review
The limited review report by
Haribhakti & Co. LLP, Chartered Accountants, concluded that the financial statements comply with Indian Accounting Standards (Ind AS) and regulatory norms, with
no material misstatements.
Outlook and Strategic Initiatives
- Expansion & Market Growth: Paushak continues to explore new markets and R&D investments in high-value specialty chemicals.
- Operational Strength: The company is focusing on cost efficiency and supply chain optimization to sustain growth.
- Industry Positioning: With a strong balance sheet and healthy financial performance, Paushak remains a key player in the specialty chemicals industry.
Conclusion
Paushak Limited delivered a
resilient performance in Q3 FY2025 despite slight revenue declines. The company maintains
strong profitability, supported by
cost management and operational efficiencies. Looking ahead, strategic investments and industry demand are expected to
drive future growth.